Article
Cell Biology
You-Jin Jo, Hye In Lee, Narae Kim, Donghyun Hwang, Jiae Lee, Gong-Rak Lee, Seong-Eun Hong, Hana Lee, Minjeong Kwon, Nam Young Kim, Hyun Jin Kim, Jin Ha Park, Ye Hee Kang, Han Sung Kim, Soo Young Lee, Woojin Jeong
Summary: Studies have shown that Cinchonine inhibits osteoclast differentiation by regulating TAK1 to suppress NFATc1 and PGC1 beta, leading to the suppression of osteoclast differentiation and promotion of osteoblast differentiation. Furthermore, Cinchonine exhibits potential therapeutic effects in mouse models of inflammation-induced bone diseases and postmenopausal osteoporosis.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Cell Biology
Xudong Xie, Liangcong Hu, Bobin Mi, Adriana C. Panayi, Hang Xue, Yiqiang Hu, Guodong Liu, Lang Chen, Chenchen Yan, Kangkang Zha, Ze Lin, Wu Zhou, Fei Gao, Guohui Liu
Summary: With the increasing global aging population, the prevalence of osteoporosis, especially among postmenopausal women, is on the rise. Developing new treatment options is, therefore, crucial. This study investigated the potential use of AQX-1125, an activator of inositol phosphatase-1 (SHIP1), and found that it demonstrated a protective effect against bone loss in ovariectomized (OVX) mice. This effect was attributed to the promotion of osteogenesis and mineralization and inhibition of osteoclastogenesis in a time- and dose-dependent manner. The protective effect was identified to be SHIP1-dependent, as the inhibition of SHIP1 using RNA interference diminished the osteoprotective effects. Furthermore, in vivo administration of SHIP1 RNA interference resulted in significant bone loss and decreased bone mass. Mechanistically, AQX-1125 upregulated the expression and activity of SHIP1, consequently upregulating the phosphorylation levels of PI3K and Akt, leading to the promotion of osteoblast-related gene expressions and the inhibition of NF-kappa B signaling and osteoclastogenesis.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Takuma Matsubara, Kazuma Yasuda, Kana Mizuta, Hiroka Kawaue, Shoichiro Kokabu
Summary: Osteoclasts and osteoblasts are the key cells regulating bone homeostasis. Imbalance between increased bone resorption by osteoclasts and decreased bone formation by osteoblasts leads to osteoporosis and other metabolic bone diseases. Src has been identified as an essential factor for bone resorption and a suppressor of bone formation. However, developing effective therapies targeting Src is challenging due to its widespread expression and involvement in various biological processes. Understanding the molecular mechanism of Src in bone is crucial for the treatment of bone metabolic diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Vishwa Deepak, Shu-Ting Yang, Ziqing Li, Xinhua Li, Andrew Ng, Ding Xu, Yi-Ping Li, Merry Jo Oursler, Shuying Yang
Summary: This study identifies a negative function of IFT80 in osteoclasts by regulating the stabilization and degradation of Cbl-b and TRAF6, thereby affecting osteoclast formation.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Cell Biology
Zhihai Cao, Yuan Xue, Jiaqian Wang
Summary: Osteoporosis is caused by decreased bone formation and increased bone absorption, with ferroptosis playing a key role. Ferroptosis may inhibit bone formation and promote bone absorption through oxidative stress, leading to osteoporosis.
Article
Pharmacology & Pharmacy
Kangtao Jin, Lin Zheng, Lin Ye, Ziang Xie, Jiawei Gao, Chao Lou, Wenzheng Pan, Bin Pan, Shijie Liu, Zhenzhong Chen, Dengwei He
Summary: The study demonstrates that CSB6B suppresses osteoclast differentiation and bone resorption while enhancing osteoblast mineralization by inhibiting the NF-KB pathway and promoting Runx expression. In murine models, CSB6B has shown protective effects against pathological bone destruction and bone loss induced by estrogen deficiency. MIF inhibition by CSB6B could be a potential therapeutic approach for osteolytic bone disorders and osteoporosis.
BIOCHEMICAL PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Shenglei Yang, Yuying Sun, Leonid Kapilevich, Xin'an Zhang, Yue Huang
Summary: Osteoporosis is a common skeletal disorder that primarily affects the elderly and postmenopausal women. Drug therapy is currently used as the main treatment, but long-term use can lead to drug resistance and side effects. Therefore, researchers are exploring natural plant compounds as an alternative. Curcumin, a natural phenolic compound, has shown potential as a candidate for treating osteoporosis due to its various pharmacological and biological activities. This review summarizes the mechanisms and therapeutic applications of curcumin in preventing and mitigating osteoporosis, providing valuable references for further research and development of curcumin.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Food Science & Technology
Ilandarage Menu Neelaka Molagoda, Athapaththu Mudiyanselage Gihan Kavinda Athapaththu, Eui Kyun Park, Yung Hyun Choi, You-Jin Jeon, Gi-Young Kim
Summary: This study evaluated the osteogenic potential of gamma aminobutyric acid-enriched fermented oyster extract (FO) on prednisolone-induced bone resorption. The results showed that FO can restore osteogenic activity and improve osteoblast markers in MC3T3-E1 preosteoblast cells and zebrafish larvae. Additionally, FO also restored vertebral resorption induced by prednisolone in zebrafish larvae, along with downregulation of osteoclastogenic markers. Importantly, FO did not disturb the endocrine system.
Article
Biochemistry & Molecular Biology
Jung Ha Kim, Kabsun Kim, Inyoung Kim, Semun Seong, Jeong-Tae Koh, Nacksung Kim
Summary: ATF3 regulates the differentiation of various cell types in the bone microenvironment, including osteoblasts, osteoclasts, and adipocytes, by inducing OPG production.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Ye-Eun Choi, Jung-Mo Yang, Ju-Hyun Cho
Summary: Due to global population aging, instances of bone metabolic diseases have increased. This study shows the potential therapeutic effects of Benincasa hispida extract in preventing and treating osteoporosis by promoting osteogenesis and inhibiting osteoclast differentiation. The results suggest that HR1901-W is a promising candidate for regulating the balance between bone-forming osteoblasts and bone-resorbing osteoclasts to prevent osteoporosis.
APPLIED SCIENCES-BASEL
(2022)
Article
Cell & Tissue Engineering
Xiankun Cao, Wenxin He, Kewei Rong, Shenggui Xu, Zhiqian Chen, Yuwei Liang, Shuai Han, Yifan Zhou, Xiao Yang, Hui Ma, An Qin, Jie Zhao
Summary: This study revealed that DZNep enhances osteoblast differentiation and mineralization through the EZH2-H3K27me3-Wnt4 axis, while also promotes osteoclast formation via the EZH2-H3K27me3-Foxc1 axis. This enhanced osteogenesis and osteoclastogenesis resulted in accelerated bone defect healing in mice.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Cell Biology
Hyun Jin Kim, Jiae Lee, Gong-Rak Lee, Narae Kim, Hye In Lee, Minjeong Kwon, Nam Young Kim, Jin Ha Park, Ye Hee Kang, Hyeong Ju Song, TaeSoo Kim, Dong Min Shin, Woojin Jeong
Summary: FN inhibits osteoclastogenesis by blocking CaMKIV and calcineurin, reducing the risk of bone diseases like osteoporosis.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Chao Liu, Yining Li, Ren Sheng, Xiaowan Han, Li Bao, Chenyin Wang, Weizhi Wang, Xinhai Jiang, Jiangxue Han, Lijuan Lei, Ni Li, Jing Zhang, Minghua Chen, Yan Li, Yexiang Wu, Shunwang Li, Yu Ren, Yanni Xu, Shuyi Si
Summary: The study demonstrated that the N-methylpyridine-chlorofuranformamide analog 3i1 shows promise in upregulating OPG activity, inhibiting RANKL-induced osteoclastogenesis, and promoting osteoblast differentiation, potentially serving as a new therapeutic agent for osteoporosis.
BIOORGANIC CHEMISTRY
(2021)
Review
Chemistry, Medicinal
Sophia Ogechi Ekeuku, Kok-Lun Pang, Kok-Yong Chih
Summary: Caffeic acid, a metabolite of hydroxycinnamate and phenylpropanoid, acts as an antioxidant to reduce osteoclastogenesis and bone resorption. However, in some cases, it may have no effect on bone resorption or even impair bone mechanical properties in normal rats.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Engineering, Biomedical
Wei Zhang, Xingzhi Zhou, Weiduo Hou, Erman Chen, Chenyi Ye, Mo Chen, Qian Lu, Xiaohua Yu, Weixu Li
Summary: In this study, a molecular therapeutic strategy mediated by a SIRT-1 agonist was reported to reverse the imbalance in bone homeostasis by regulating osteogenesis and osteoclastogenesis simultaneously. The sustained release of SRT2104 from mineral coated acellular matrix microparticles effectively enhanced osteogenic differentiation and mineralization, while attenuating the formation and function of excessive osteoclasts by integrating multiple vital upstream signals. Animal models also demonstrated the accelerated healing and improved osseointegration of osteoporotic bone defects.
BIOACTIVE MATERIALS
(2023)